Skip Navigation

European Heart Journal 2003 24(4):297-298; doi:10.1016/S0195-668X(02)00753-4
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gibbs, J.S. R
Right arrow Articles by Wilkins, M. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibbs, J.S. R
Right arrow Articles by Wilkins, M. R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing?

J.Simon R Gibbsa,b,*, John Whartona,b and Martin R Wilkinsa,b

a National Heart & Lung Institute and Section on Clinical Pharmacology, Imperial College London, London, UK
b Hammersmith Hospital, Du Cane Road, London W12 0HS, UK

Received October 8, 2002; accepted October 9, 2002 * Corresponding author. Department of Cardiology, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK. Tel.: +44-208-383-2330; fax: +44-208-383-2331
s.gibbs@ic.ac.uk

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(02)00302-0for the article to which this editorial refers.

Recent years have witnessed a transformation in the treatments available for patients with pulmonary arterial hypertension with the development of new therapies that offer significant therapeutic benefit. While the inspiration behind them may have been based on tipping a perceived imbalance in vasoconstrictor–vasodilator activity towardsvasodilation, it is emerging that the main action of these new treatments is to prevent (and possibly reverse) pulmonary vascular remodelling. Should this insight change our protocol for investigating and working up . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Assessment of the vasodilator response in primary pulmonary hypertension: Comparing prostacyclin and iloprost administered by either infusion or inhalation
C.F Opitz, R Wensel, M Bettmann, R Schaffarczyk, M Linscheid, R Hetzer, and R Ewert
EHJ 2003 24: 356-365. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
G. W Mikhail, S. K Prasad, W. Li, P. Rogers, A. H Chester, S. Bayne, D. Stephens, M. Khan, J.S.R Gibbs, T. W Evans, et al.
Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects
Eur. Heart J., March 1, 2004; 25(5): 431 - 436.
[Abstract] [Full Text] [PDF]